<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1">
<meta charset="utf-8">
<title>DailyMed - MEXILETINE HCL- mexiletine hydrochloride
capsule</title>
<!--[if lt IE 9]>
        <script src="/dailymed/scripts/html5shiv.min.js"></script>
    <![endif]-->

<script src="/dailymed/scripts/modernizr-2.0.6.min.js">
</script>
<link rel="stylesheet" type="text/css" media="screen" href=
"/dailymed/css/skeleton.min.css">
<link rel="stylesheet" type="text/css" media="screen" href=
"/dailymed/css/jquery.jqzoom.min.css">
<link rel="stylesheet" type="text/css" media="screen" href=
"/dailymed/css/style.min.css?v=2">
<link rel="stylesheet" type="text/css" media="screen" href=
"/dailymed/css/header-search.min.css">
<link rel="stylesheet" type="text/css" media="all" href=
"/dailymed/css/responsive.min.css">
<link rel="stylesheet" type="text/css" media="print" href=
"/dailymed/css/print.min.css"><!--[if !IE]><!-->
<link rel="stylesheet" type="text/css" media="all" href=
"/dailymed/css/responsive-tables.min.css"><!--<![endif]-->
<link rel="icon" href="/dailymed/images/favicons/favicon.ico" type=
"image/x-icon">
<link rel="shortcut icon" href=
"/dailymed/images/favicons/favicon.ico" type="image/x-icon">
<link rel="apple-touch-icon" sizes="57x57" href=
"/dailymed/images/favicons/apple-touch-icon-57x57.png">
<link rel="apple-touch-icon" sizes="114x114" href=
"/dailymed/images/favicons/apple-touch-icon-114x114.png">
<link rel="apple-touch-icon" sizes="72x72" href=
"/dailymed/images/favicons/apple-touch-icon-72x72.png">
<link rel="apple-touch-icon" sizes="144x144" href=
"/dailymed/images/favicons/apple-touch-icon-144x144.png">
<link rel="apple-touch-icon" sizes="60x60" href=
"/dailymed/images/favicons/apple-touch-icon-60x60.png">
<link rel="apple-touch-icon" sizes="120x120" href=
"/dailymed/images/favicons/apple-touch-icon-120x120.png">
<link rel="apple-touch-icon" sizes="76x76" href=
"/dailymed/images/favicons/apple-touch-icon-76x76.png">
<link rel="apple-touch-icon" sizes="152x152" href=
"/dailymed/images/favicons/apple-touch-icon-152x152.png">
<link rel="icon" type="image/png" href=
"/dailymed/images/favicons/favicon-196x196.png" sizes="196x196">
<link rel="icon" type="image/png" href=
"/dailymed/images/favicons/favicon-160x160.png" sizes="160x160">
<link rel="icon" type="image/png" href=
"/dailymed/images/favicons/favicon-96x96.png" sizes="96x96">
<link rel="icon" type="image/png" href=
"/dailymed/images/favicons/favicon-16x16.png" sizes="16x16">
<link rel="icon" type="image/png" href=
"/dailymed/images/favicons/favicon-32x32.png" sizes="32x32">
<meta name="msapplication-config" content=
"/dailymed/images/favicons/browserconfig.xml">
<meta name="msapplication-TileColor" content="#da532c">
<meta name="msapplication-TileImage" content=
"/dailymed/images/favicons/mstile-144x144.png">
<meta name="description" content="">
<meta name="keywords" content="">
<meta name="robots" content="noimageindex, noodp, noydir">
<meta name="viewport" id="viewport" content=
"width=device-width,minimum-scale=1.0,maximum-scale=10.0,initial-scale=1.0"><!-- Magnific Popup core CSS file -->
<link rel="stylesheet" href="/dailymed/css/magnific-popup.min.css">
<meta name="format-detection" content="telephone=no">
</head>
<body class="inner drug-info">
<div class="container_1000 bg_shadow">
<div style="width: 0; height: 0;"><a href="#" id=
"top-of-page"></a></div>
<header>
<div class="topHeader">
<ul id="skip">
<li><a href="#skip-main-content">Skip to Main Content</a></li>
</ul>
<nav class="topHeaderNav">
<div class="topNIHLogo mobileview"><a href="http://www.nih.gov"
class="top-logo" title="National Institutes of Health" target=
"_blank"><img src="/dailymed/images/nih-toplogo.png" alt=
"NIH Logo"></a> <a href="//www.nlm.nih.gov" title=
"U.S. National Library of Medicine" target="_blank">U.S. National
Library of Medicine</a></div>
<div class="container">
<div class="sixteen columns">
<div class="topNIHLogo"><a href="http://www.nih.gov" title=
"National Institutes of Health" target="_blank"><img src=
"/dailymed/images/nih-toplogo.png" alt="NIH Logo"></a> <a href=
"//www.nlm.nih.gov" title="U.S. National Library of Medicine"
target="_blank">U.S. National Library of Medicine</a></div>
<ul>
<li class="safety"><a title="Report Adverse Events" href=
"//www.accessdata.fda.gov/scripts/medwatch/" target="_blank">Report
Adverse Events</a> <span>|</span><a title=
"FDA Safety Reporting and Recalls" href=
"http://www.fda.gov/Safety/Recalls" target=
"_blank">Recalls</a></li>
</ul>
</div>
</div>
</nav>
<div class="divider"></div>
</div>
<div class="dailymedlogoprint"><img src="/dailymed/images/logo.png"
alt="DailyMed"></div>
<div class="bottomHeader">
<div class="header-image">
<div class="mobile-menu-btn closed hasjs" tabindex="0"></div>
<div class="mobile-menu">
<div class="mobile-menu-container">
<div class="pro-menu active">
<div class="first half">
<ul>
<li><a href="/dailymed/index.cfm">Home</a></li>
<li>News
<ul>
<li><a href="/dailymed/dailymed-announcements.cfm">DailyMed
Announcements</a></li>
<li><a href="/dailymed/rss-updates.cfm">Get RSS News &amp;
Updates</a></li>
</ul>
</li>
<li><a href="/dailymed/about-dailymed.cfm">About Dailymed</a></li>
<li><a href="/dailymed/contact-us.cfm">Contact Us</a></li>
<li>Safety Reporting &amp; Recalls
<ul>
<li><a href="//www.accessdata.fda.gov/scripts/medwatch/">Report
Adverse Events</a></li>
<li><a href="http://www.fda.gov/Safety/Recalls">FDA Saftey
Recalls</a></li>
</ul>
</li>
<li><a href="/dailymed/fda-drug-guidance.cfm">FDA Guidances &amp;
Information</a></li>
</ul>
</div>
<div class="last half">
<ul>
<li>NLM SPL Resources
<ul>
<li><a href="/dailymed/spl-resources.cfm">Download Data</a>
<ul>
<li><a href="/dailymed/spl-resources-all-drug-labels.cfm">- All
Drug Labels</a></li>
<li><a href="/dailymed/spl-resources-all-indexing-files.cfm">- All
Indexing Files</a></li>
<li><a href="/dailymed/spl-resources-all-mapping-files.cfm">- All
Mapping Files</a></li>
</ul>
</li>
<li><a href="/dailymed/splimage-guidelines.cfm">SPL Image
Guidelines</a></li>
<li><a href=
"/dailymed/spl-resources-all-mapping-files.cfm">Articles &amp;
Presentations</a></li>
</ul>
</li>
<li>Application Development Support
<ul>
<li><a href="/dailymed/app-support.cfm">Resources</a>
<ul>
<li><a href="/dailymed/app-support-web-services.cfm">- Web
Services</a></li>
<li><a href="/dailymed/app-support-mapping-files.cfm">- Mapping
Files</a></li>
</ul>
</li>
</ul>
</li>
<li><a href="/dailymed/help.cfm">Help</a></li>
</ul>
</div>
</div>
</div>
</div>
<a href="/dailymed/index.cfm" class="logo" title=
"DailyMed">DailyMed</a>
<div class="header-search-container">
<div id="header-search">
<form action="/dailymed/search.cfm">
<div class="searchNav">
<ul class="searchType">
<li class="all active"><input type="radio" class="hidden" name=
"labeltype" id="labeltype-all" value="all"> <label for=
"labeltype-all">All Drugs</label></li>
<li class="human"><input type="radio" class="hidden" name=
"labeltype" id="labeltype-human" value="human"> <label for=
"labeltype-human">Human Drugs</label></li>
<li class="animal"><input type="radio" class="hidden" name=
"labeltype" id="labeltype-animal" value="animal"> <label for=
"labeltype-animal">Animal Drugs</label></li>
<li class="more-ways" id="header-search-more-ways"><a href="#" id=
"more-ways-button" class="more-ways-label">More ways to search</a>
<ul id="more-ways-dropdown" class="dropdown" style="display:none;">
<li><a href="/dailymed/advanced-search.cfm">Advanced
Search</a></li>
<li><a href="/dailymed/browse-drug-classes.cfm">Browse Drug
Classes</a></li>
<li><a href="/dailymed/archives/index.cfm">Label Archives</a></li>
<li><a class="external-link" href="http://pillbox.nlm.nih.gov"
target="_blank">Tablet/Capsule ID Tool</a></li>
</ul>
</li>
</ul>
</div>
<div class="searchForm">
<div class="searchInput"><input id="searchQuery" name="query"
tabindex="0" type="text" placeholder=
"Enter drug, NDC code, drug class, or Set ID" autocorrect="off"
autocapitalize="off"></div>
<input class="search" tabindex="0" title="Search" type="submit"
value="Search"></div>
</form>
</div>
</div>
<div class="mobile-search-btn" tabindex="0"></div>
<div class="header-bg"></div>
<div class="divider"></div>
</div>
<div class="bottomHeaderContent">
<div class="search mobile-search">
<div class="divider_10 nomargin mobileview"></div>
<form action="/dailymed/search.cfm">
<div class="searchNav">
<ul class="searchType">
<li class="all active"><input type="radio" class="hidden" name=
"labeltype" id="labeltype-all-2" value="all"> <label for=
"labeltype-all-2">All Drugs</label></li>
<li class="human"><input type="radio" class="hidden" name=
"labeltype" id="labeltype-human-2" value="human"> <label for=
"labeltype-human-2">Human Drugs</label></li>
<li class="animal"><input type="radio" class="hidden" name=
"labeltype" id="labeltype-animal-2" value="animal"> <label for=
"labeltype-animal-2">Animal Drugs</label></li>
</ul>
</div>
<div class="searchForm">
<div class="searchInput"><input id="searchToolsQuery" name="query"
tabindex="0" type="text" placeholder=
"Enter drug, NDC code, drug class, or Set ID" autocorrect="off"
autocapitalize="off"></div>
<input class="search" tabindex="0" title="Search" type="submit"
value="Search"></div>
</form>
<div class="divider"></div>
<nav class="bottomHeaderNav"><noscript>
<div class="tabletnav no-js">
<div class="col">
<ul>
<li><a href="/dailymed/index.cfm">Home</a></li>
<li>News
<ul>
<li><a href="/dailymed/dailymed-announcements.cfm">DailyMed
Announcements</a></li>
<li><a href="/dailymed/rss-updates.cfm">Get RSS News &amp;
Updates</a></li>
</ul>
</li>
</ul>
</div>
<div class="col">
<ul>
<li>Search
<ul>
<li><a href="/dailymed/advanced-search.cfm">Advanced
Search</a></li>
<li><a href="/dailymed/browse-drug-classes.cfm">Browse Drug
Classes</a></li>
<li><a href="/dailymed/archives/index.cfm">Labels Archives</a></li>
<li><a href="http://pillbox.nlm.nih.gov">Tablet/Capsule ID
Tool</a></li>
</ul>
</li>
</ul>
</div>
<div class="col">
<ul>
<li><a href="/dailymed/fda-drug-guidance.cfm">FDA Guidances &amp;
Information</a></li>
<li>NLM SPL Resources
<ul>
<li><a href="/dailymed/spl-resources.cfm">Download Data</a>
<ul>
<li><a href="/dailymed/spl-resources-all-drug-labels.cfm">All Drug
Labels</a></li>
<li><a href="/dailymed/spl-resources-all-indexing-files.cfm">All
Index Files</a></li>
<li><a href="/dailymed/spl-resources-all-mapping-files.cfm">All
Mapping Files</a></li>
</ul>
</li>
<li><a href="/dailymed/splimage-guidelines.cfm">SPL Image
Guidelines</a></li>
<li><a href=
"/dailymed/spl-resources-presentations-articles.cfm">Presentations
&amp; Articles</a></li>
</ul>
</li>
</ul>
</div>
<div class="col">
<ul>
<li>Application Development Support
<ul>
<li><a href="/dailymed/app-support.cfm">Resources</a>
<ul>
<li><a href="/dailymed/app-support-web-services.cfm">Web
Services</a></li>
<li><a href="/dailymed/app-support-mapping-files.cfm">Mapping
Files</a></li>
</ul>
</li>
</ul>
</li>
<li><a href="/dailymed/help.cfm">Help</a></li>
</ul>
</div>
</div>
</noscript>
<ul class="webview hasjs">
<li><a href="/dailymed/index.cfm" title="Home">Home</a></li>
<li><a href="#" title="News">News</a>
<ul class="sub-menu">
<li><a href="/dailymed/dailymed-announcements.cfm">DailyMed
Announcements</a></li>
<li><a href="/dailymed/rss-updates.cfm">Get RSS News &amp;
Updates</a></li>
</ul>
</li>
<li><a href="/dailymed/fda-drug-guidance.cfm" title=
"FDA Guidances &amp; Info">FDA Guidances &amp; Info</a></li>
<li><a href="#" title=
"Structured Product Labeling (SPL) resources for industry professionals.">
NLM SPL Resources</a>
<ul class="sub-menu">
<li><a href="/dailymed/spl-resources.cfm">Download Data</a>
<ul>
<li><a href="/dailymed/spl-resources-all-drug-labels.cfm">All Drug
Labels</a></li>
<li><a href="/dailymed/spl-resources-all-indexing-files.cfm">All
Indexing Files</a></li>
<li><a href="/dailymed/spl-resources-all-mapping-files.cfm">All
Mapping Files</a></li>
</ul>
</li>
<li><a href="/dailymed/splimage-guidelines.cfm">SPL Image
Guidelines</a></li>
<li><a href=
"/dailymed/spl-resources-presentations-articles.cfm">Presentations
&amp; Articles</a></li>
</ul>
</li>
<li><a href="#" title="Application Development Support">Application
Development Support</a>
<ul class="sub-menu">
<li><a href="/dailymed/app-support.cfm">Resources</a>
<ul>
<li><a href="/dailymed/app-support-web-services.cfm">Web
Services</a></li>
<li><a href="/dailymed/app-support-mapping-files.cfm">Mapping
Files</a></li>
</ul>
</li>
</ul>
</li>
<li><a href="/dailymed/help.cfm" title="Help">Help</a></li>
</ul>
<ul class="tabletview hasjs">
<li><a href="/dailymed/advanced-search.cfm" title=
"Advanced Search">Advanced Search</a></li>
<li class="viewmore"><a href="#" title="View More">View More</a>
<ul>
<li><span>News</span>
<ul>
<li><a href="/dailymed/dailymed-announcements.cfm">DailyMed
Announcements</a></li>
<li><a href="/dailymed/rss-updates.cfm">Get RSS News &amp;
Updates</a></li>
</ul>
</li>
<li><span>Safety Reporting and Recalls</span>
<ul>
<li><a href="//www.accessdata.fda.gov/scripts/medwatch/" target=
"_blank">Report Adverse Events</a></li>
<li><a href="//www.fda.gov/Safety/Recalls" target="_blank">FDA
Saftey Recalls</a></li>
</ul>
</li>
<li><a href="/dailymed/fda-drug-guidance.cfm">FDA Guidances &amp;
Information</a></li>
<li><span>NLM SPL Resources</span>
<ul>
<li><a href="/dailymed/spl-resources.cfm">Download Data</a>
<ul>
<li><a href="/dailymed/spl-resources-all-drug-labels.cfm">- All
Drug Labels</a></li>
<li><a href="/dailymed/spl-resources-all-indexing-files.cfm">- All
Indexing Files</a></li>
<li><a href="/dailymed/spl-resources-all-mapping-files.cfm">- All
Mapping Files</a></li>
</ul>
</li>
<li><a href="/dailymed/splimage-guidelines.cfm">SPL Image
Guidelines</a></li>
<li><a href=
"/dailymed/spl-resources-presentations-articles.cfm">Presentations
&amp; Articles</a></li>
</ul>
</li>
<li><span>Application Development Support</span>
<ul>
<li><a href="/dailymed/app-support.cfm">Resources</a>
<ul>
<li><a href="/dailymed/app-support-web-services.cfm">- Web
Services</a></li>
<li><a href="/dailymed/app-support-mapping-files.cfm">- Mapping
Files</a></li>
</ul>
</li>
</ul>
</li>
<li><a href="/dailymed/help.cfm" title="Help">Help</a></li>
</ul>
</li>
<li class="mobileview viewmore" tabindex="0"><a title="View More"
href="#">More ways to search</a>
<ul>
<li tabindex="0"><a title="Browse Drug Classes" href=
"/dailymed/browse-drug-classes.cfm">Browse Drug Classes</a></li>
<li tabindex="0"><a title="Label Archives" href=
"/dailymed/archives/index.cfm">Label Archives</a></li>
<li tabindex="0"><a target="_blank" title="Tablet/Capsule ID Tool"
href="http://pillbox.nlm.nih.gov/">Tablet/Capsule ID Tool</a></li>
</ul>
</li>
</ul>
<ul class="mobileview hasjs">
<li><a href="/dailymed/advanced-search.cfm" title=
"Advanced Search">Advanced Search</a></li>
<li tabindex="0" class="viewmore"><a href="#" title=
"View More">View More</a>
<ul>
<li tabindex="0"><a href="/dailymed/browse-drug-classes.cfm" title=
"Browse Drug Classes">Browse Drug Classes</a></li>
<li tabindex="0"><a href="/dailymed/archives/index.cfm" title=
"Label Archives">Label Archives</a></li>
<li tabindex="0"><a href="http://pillbox.nlm.nih.gov/" title=
"Tablet/Capsule ID Tool" target="_blank">Tablet/Capsule ID
Tool</a></li>
</ul>
</li>
</ul>
</nav>
<div class="divider_10 nomargin"></div>
</div>
</div>
<div class="divider"></div>
</div>
</header>
<div id="skip-main-content"></div>
<div class="container">
<div class="main-content">
<div class="header long">
<div class="header-top">
<h1>Label: <span class="long-title">MEXILETINE HCL- mexiletine
hydrochloride capsule<br></span></h1>
</div>
<ul class="tools">
<li class="rss"><a href="#modal-label-rss" class="modal-open">Label
RSS</a></li>
<li class="share">Share <noscript>: JavaScript needed for Sharing
tools</noscript> <!-- AddThis Button BEGIN -->
<div class=
"addthis_toolbox addthis_default_style addthis_16x16_style">
<a class="email-share" href=
"mailto:?subject=DailyMed%20Web%20site%20information&amp;Body=I%20would%20like%20to%20share%20this%20page%20from%20the%20DailyMed%20website%20with%20you%3A%0A%0AMEXILETINE%20HCL%2D%20Mexiletine%20Hydrochloride%20Capsule%0Ahttps%3A%2F%2Fdailymed%2Enlm%2Enih%2Egov%2Fdailymed%2FdrugInfo%2Ecfm%3Fsetid%3DAB73778B%2D6794%2D441C%2DB127%2D610A6D0733EA%0A%0ADailyMed%20is%20a%20site%20provided%20by%20The%20National%20Library%20of%20Medicine%20%28NLM%29%20and%20is%20the%20official%20provider%20of%20FDA%20drug%20label%20information%20%28package%20inserts%29%2E"
title="Share by Email"></a> <a class="addthis_button_facebook"></a>
<a class="addthis_button_twitter"></a> <a class=
"at300bs at15nc at15t_compact reveal" title="Bookmark &amp; Share"
href=
"//www.addthis.com/bookmark.php?pub=DailyMed&amp;title=DailyMed"
target="_blank" style="display: block;"><span style=
"left: -9999px; position: absolute;">Bookmark &amp;
Share</span><img style="width:17px" src=
"/dailymed/images/addthis-image.jpg"></a></div>
<script type="text/javascript">
var addthis_config = {"data_track_addressbar":false};
</script> <script type="text/javascript" src=
"//s7.addthis.com/js/300/addthis_widget.js#pubid=ra-542300cc2097c8b5">
</script> <!-- AddThis Button END --></li>
</ul>
</div>
<div class="four columns sidebar" id="leftmenu">
<section>
<article>
<div class="w-photos">
<div class="mod drug-photos">
<h2><a>VIEW DRUG PHOTOS</a></h2>
<div class="no-pill-photo-warning-drug-info">DailyMed is no longer
displaying pill images from RxImage. For more information, <a href=
"#no-pill-photo-warning-modal" class="modal-open">click
here</a>.</div>
</div>
</div>
<div class="mod-wrap">
<div class="mod blue-list page-jump">
<h2><a href="#drug-information">Drug Label Info</a></h2>
</div>
<div class="mod blue-list orange">
<h2><a href="#">Safety</a></h2>
<ul>
<li><a href="//www.accessdata.fda.gov/scripts/medwatch/" target=
"_blank">Report Adverse Events</a></li>
<li><a href="http://www.fda.gov/Safety/Recalls/" target=
"_blank">FDA Safety Recalls</a></li>
<li><a href=
"http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+lactmed:@or+%28@na+%22Mexiletine%22+%29"
target="_blank">Presence in Breast Milk</a></li>
</ul>
</div>
<div class="mod blue-list">
<h2><a href="#">Related Resources</a></h2>
<ul>
<li><a href=
"//vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v:project=medlineplus&amp;query=Mexiletine"
target="_blank">Medline Plus</a></li>
<li><a href=
"//www.clinicaltrials.gov/ct/search?submit=Search&amp;term=Mexiletine"
target="blank">Clinical Trials</a></li>
<li><a href="#" id="pubmed-menu">PubMed</a>
<ul>
<li><a href=
"//www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=Mexiletine[All%20Fields]"
title="Link opens new window for All Citations" target="pubmed">All
Citations</a></li>
<li><a href=
"//www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=Mexiletine/AE"
title="Link opens new window for Adverse Effects" target=
"pubmed">Adverse Effects</a></li>
<li><a href=
"//www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=Mexiletine/TU"
title="Link opens new window for Therapeutic Use" target=
"pubmed">Therapeutic Use</a></li>
<li><a href=
"//www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=Mexiletine/PD"
title="Link opens new window for Pharmacology" target=
"pubmed">Pharmacology</a></li>
<li><a href=
"//www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=Mexiletine[All%20Fields]%20AND%20Clinical%20Trial[ptyp]"
title="Link opens new window for Clinical Trials" target=
"pubmed">Clinical Trials</a></li>
</ul>
</li>
<li><a href=
"http://www.drugbank.ca/search?utf8=%E2%9C%93&amp;query=APRD00242&amp;search_type=drugs&amp;button="
target="_blank">Biochemical Data Summary</a></li>
</ul>
</div>
<div class="mod blue-list">
<h2><a href="#">More Info For This Drug</a></h2>
<ul>
<li><a href="#modal-label-archives" class="modal-open">View Label
Archives</a></li>
<li><a href="#modal-rx-norm" class="modal-open">RxNorm</a></li>
<li><a href="#modal-label-rss" class="modal-open">Get Label RSS
Feed</a></li>
</ul>
</div>
</div>
</article>
</section>
</div>
<div class="content-wide">
<article>
<ul class="drug-information">
<li><strong><a class="tip" rel="tooltip" title=
"&lt;b&gt;NDC (National Drug Code)&lt;/b&gt; - Each drug product is assigned this unique number which can be found on the drug's outer packaging."
href="#">NDC Code(s):</a></strong> <span id=
"item-code-s">0591-0491-01, 0591-0491-05, 0591-0492-01,
0591-0492-05, <a class="view-more show-js" href="#">view
more</a></span>
<div class="more-codes"><span id="item-code-s"><span>0591-0493-01,
0591-0493-05</span></span></div>
</li>
<li><strong>Packager:</strong> Watson Laboratories, Inc.</li>
</ul>
<ul class="drug-information">
<li><strong>Category:</strong> <span id="category" class=
"orangetext">HUMAN PRESCRIPTION DRUG LABEL</span></li>
<li><strong>DEA Schedule:</strong> <span id=
"dea-schedule">None</span></li>
<li><strong>Marketing Status:</strong> <span id=
"marketing-status"></span></li>
</ul>
<div id="drug-information" class="toggle">
<h2><a id="druglabel"></a>Drug Label Information</h2>
<p class="date">Updated April 29, 2008</p>
<p class="orangetext">If you are a consumer or patient please visit
<a class="audience-context-switch consumer" href=
"/dailymed/drugInfo.cfm?setid=AB73778B-6794-441C-B127-610A6D0733EA&amp;audience=consumer">
this version.</a></p>
<ul class="tools">
<li class="download">Download DRUG LABEL INFO: <a download=""
class="pdf" href=
"/dailymed/getFile.cfm?setid=AB73778B-6794-441C-B127-610A6D0733EA&amp;type=pdf&amp;name=AB73778B-6794-441C-B127-610A6D0733EA"
target="_blank">PDF</a> <a download="" class="xml" href=
"/dailymed/getFile.cfm?setid=AB73778B-6794-441C-B127-610A6D0733EA&amp;type=zip&amp;name=Mexiletine%20HCl"
target="_blank">XML</a></li>
<li class="print"><a href=
"/dailymed/fda/fdaDrugXsl.cfm?setid=AB73778B-6794-441C-B127-610A6D0733EA&amp;type=display"
target="_blank">Print Drug Label Info</a></li>
</ul>
<div class="drug-label-sections">
<div class="control-nav show-js"><a class="open-all" href="#">View
All Sections</a><a class="close-all" href="#">Close All
Sections</a></div>
<ul>
<li><a href="#">DESCRIPTION</a>
<div class="Section toggle-content closed" data-sectioncode=
"34089-3"><a name="section-2" id="section-2"></a>
<p class="First">Mexiletine hydrochloride is an orally active
antiarrhythmic agent available as 150 mg, 200 mg and 250 mg
capsules. 100 mg of mexiletine hydrochloride is equivalent to 83.31
mg of mexiletine base. It is a white to off-white crystalline
powder with slightly bitter taste, freely soluble in water and in
alcohol. Mexiletine hydrochloride has a pKa of 9.2.</p>
<p>Chemically, mexiletine hydrochloride is (±)-1-methyl-2-(2,
6-xylyloxy) ethylamine hydrochloride. Its molecular formula is
C<span class="Sub">11</span>H<span class="Sub">17</span>NO•HCI and
molecular weight is 215.72.</p>
<p>Following is its structural formula:</p>
<div class="Figure"><img src=
"image.cfm?setid=AB73778B-6794-441C-B127-610A6D0733EA&amp;name=mexiletine-figure-01.jpg"
alt="Image from Drug Label Content"></div>
<p>Each capsule, for oral administration contains 150 mg, 200 mg,
or 250 mg mexiletine hydrochloride. In addition, each capsule
contains the following inactive ingredients: colloidal silicon
dioxide, corn starch, D&amp;C Red No. 28, D&amp;C Yellow No. 10,
FD&amp;C Blue No. 1, FD&amp;C Red No. 40, gelatin, magnesium
stearate, pregelatinized starch, sodium lauryl sulfate, and
titanium dioxide. Mexiletine hydrochloride capsules 150 mg also
contain black iron oxide, red iron oxide, and yellow iron oxide.
Mexiletine hydrochloride capsules 250 mg also contain FD&amp;C
Green No. 3.</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">CLINICAL PHARMACOLOGY</a>
<div class="Section toggle-content closed" data-sectioncode=
"34090-1"><a name="section-3" id="section-3"></a>
<p class="First"><span class="Bold">Mechanism of Action:</span>
Mexiletine hydrochloride is a local anesthetic, antiarrhythmic
agent, structurally similar to lidocaine, but orally active. In
animal studies, mexiletine has been shown to be effective in the
suppression of induced ventricular arrhythmias, including those
induced by glycoside toxicity and coronary artery ligation.
Mexiletine, like lidocaine, inhibits the inward sodium current,
thus reducing the rate of rise of the action potential, Phase 0.
Mexiletine decreased the effective refractory period (ERP) in
Purkinje fibers. The decrease in ERP was of lesser magnitude than
the decrease in action potential duration (APD), with a resulting
increase in the ERP/APD ratio.</p>
<p><span class="Bold">Electrophysiology in Man:</span> Mexiletine
is a Class 1B antiarrhythmic compound with electrophysiologic
properties in man similar to those of lidocaine, but dissimilar
from quinidine, procainamide, and disopyramide.</p>
<p>In patients with normal conduction systems, mexiletine has a
minimal effect on cardiac impulse generation and propagation. In
clinical trials, no development of second-degree or third-degree AV
block was observed. Mexiletine did not prolong ventricular
depolarization (QRS duration) or repolarization (QT intervals) as
measured by electrocardiography. Theoretically, therefore,
mexiletine may be useful in the treatment of ventricular
arrhythmias associated with a prolonged QT interval.</p>
<p>In patients with pre-existing conduction defects, depression of
the sinus rate, prolongation of sinus node recovery time, decreased
conduction velocity and increased effective refractory period of
the intraventricular conduction system have occasionally been
observed.</p>
<p>The antiarrhythmic effect of mexiletine has been established in
controlled comparative trials against placebo, quinidine,
procainamide, and disopyramide. Mexiletine hydrochloride, at doses
of 200 to 400 mg q8h, produced a significant reduction of
ventricular premature beats, paired beats, and episodes of
non-sustained ventricular tachycardia compared to placebo and was
similar in effectiveness to the active agents. Among all patients
entered into the studies, about 30% in each treatment group had a
70% or greater reduction in PVC count and about 40% failed to
complete the 3 month studies because of adverse effects. Follow-up
of patients from the controlled trials has demonstrated continued
effectiveness of mexiletine in long-term use.</p>
<p><span class="Bold">Hemodynamics:</span> Hemodynamic studies in a
limited number of patients, with normal or abnormal myocardial
function, following oral administration of mexiletine
hydrochloride, have shown small, usually not statistically
significant, decreases in cardiac output and increases in systemic
vascular resistance, but no significant negative inotropic effect.
Blood pressure and pulse rate remain essentially unchanged. Mild
depression of myocardial function, similar to that produced by
lidocaine, has occasionally been observed following intravenous
mexiletine hydrochloride therapy in patients with cardiac
disease.</p>
<p><span class="Bold">Pharmacokinetics:</span> Mexiletine is well
absorbed (~90%) from the gastrointestinal tract. Unlike lidocaine,
its first-pass metabolism is low. Peak blood levels are reached in
two to three hours. In normal subjects, the plasma elimination
half-life of mexiletine is approximately 10 to 12 hours. It is 50
to 60% bound to plasma protein, with a volume of distribution of 5
to 7 liters/kg. Mexiletine is mainly metabolized in the liver, the
primary pathway being CYP2D6 metabolism, although it is also a
substrate for CYP1A2. With involvement of CYP2D6, there can be
either poor or extensive metabolizer phenotypes. Since
approximately 90% of mexiletine is metabolized in the liver into
inactive metabolites, pathological changes in the liver can
restrict hepatic clearance of mexiletine and its metabolites. The
metabolic degradation proceeds via various pathways including
aromatic and aliphatic hydroxylation, dealkylation, deamination and
N-oxidation. Several of the resulting metabolites are submitted to
further conjugation with glucuronic acid (phase II metabolism);
among these are the major metabolites p-hydroxymexiletine,
hydroxy-methylmexiletine and N-hydroxy-mexiletine. Approximately
10% is excreted unchanged by the kidney. While urinary pH does not
normally have much influence on elimination, marked changes in
urinary pH influence the rate of excretion: acidification
accelerates excretion, while alkalinization retards it. Several
metabolites of mexiletine have shown minimal antiarrhythmic
activity in animal models. The most active is the minor metabolite
N-methylmexiletine, which is less than 20% as potent as mexiletine.
The urinary excretion of N-methylmexiletine in man is less than
0.5%. Thus the therapeutic activity of mexiletine is due to the
parent compound. Hepatic impairment prolongs the elimination
half-life of mexiletine. In eight patients with moderate to severe
liver disease, the mean half-life was approximately 25 hours.</p>
<p>Consistent with the limited renal elimination of mexiletine,
little change in the half-life has been detected in patients with
reduced renal function. In eight patients with creatinine clearance
less than 10 ml/min, the mean plasma elimination half-life was 15.7
hours; in seven patients with creatinine clearance between 11 to 40
ml/min, the mean half-life was 13.4 hours.</p>
<p>The absorption rate of mexiletine is reduced in clinical
situations such as acute myocardial infarction in which gastric
emptying time is increased. Narcotics, atropine, and
magnesium-aluminum hydroxide have also been reported to slow the
absorption of mexiletine. Metoclopramide has been reported to
accelerate absorption.</p>
<p>Mexiletine plasma levels of at least 0.5 mcg/ml are generally
required for therapeutic response. An increase in the frequency of
central nervous system adverse effects has been observed when
plasma levels exceed 2 mcg/ml. Thus the therapeutic range is
approximately 0.5 to 2 mcg/ml. Plasma levels within the therapeutic
range can be attained with either three times daily or twice daily
dosing but peak to trough differences are greater with the latter
regimen, creating the possibility of adverse effects at peak and
arrhythmic escape at trough. Nevertheless, some patients may be
transferred successfully to the twice daily regimen
(see<span class="Bold"><a href=
"#A039C1CD-DCE5-45D4-8911-C26E1400B353">DOSAGE AND
ADMINISTRATION</a></span>).</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">INDICATIONS AND USAGE</a>
<div class="Section toggle-content closed" data-sectioncode=
"34067-9"><a name="section-4" id="section-4"></a>
<p class="First">Mexiletine Hydrochloride Capsules are indicated
for the treatment of documented ventricular arrhythmias, such as
sustained ventricular tachycardia, that, in the judgement of the
physician, are life-threatening. Because of the proarrhythmic
effects of mexiletine, its use with lesser arrhythmias is generally
not recommended. Treatment of patients with asymptomatic
ventricular premature contractions should be avoided.</p>
<p>Initiation of mexiletine treatment, as with other antiarrhythmic
agents used to treat life-threatening arrhythmias, should be
carried out in the hospital.</p>
<p>Antiarrhythmic drugs have not been shown to enhance survival in
patients with ventricular arrhythmias.</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">CONTRAINDICATIONS</a>
<div class="Section toggle-content closed" data-sectioncode=
"34070-3"><a name="section-5" id="section-5"></a>
<p class="First">Mexiletine hydrochloride is contraindicated in the
presence of cardiogenic shock or pre-existing second- or
third-degree AV block (if no pacemaker is present).</p>
<div class="scrollingtable">
<table frame="vsides">
<tbody class="Headless">
<tr class="First">
<td class="Rrule" valign="top"></td>
</tr>
<tr>
<td class="LruleRrule" align="center" colspan="2" valign="top">
<span class="Bold">WARNINGS</span></td>
</tr>
<tr>
<td class="LruleRrule" colspan="2" valign="top"><span class=
"Bold">Mortality: In the National Heart, Lung and Blood Institute’s
Cardiac Arrhythmia Suppression Trial (CAST), a long-term,
multicentered, randomized, double-blind study in patients with
asymptomatic non-life-threatening ventricular arrhythmias who had a
myocardial infarction more than six days but less than two years
previously, an excessive mortality or non-fatal cardiac arrest rate
(7.7%) was seen in patients treated with encainide or flecainide
compared with that seen in patients assigned to carefully matched
placebo-treated groups (3.0%). The average duration of treatment
with encainide or flecainide in this study was ten
months.</span></td>
</tr>
<tr class="Last">
<td class="LruleRrule" colspan="2" valign="top"><span class=
"Bold">The applicability of the CAST results to other populations
(e.g. those without recent myocardial infarction) is uncertain.
Considering the known proarrhythmic properties of mexiletine and
the lack of evidence of improved survival for any antiarrhythmic
drug in patients without life-threatening arrhythmias, the use of
mexiletine as well as other antiarrhythmic agents should be
reversed for patients with life-threatening ventricular
arrhythmia.</span></td>
</tr>
</tbody>
</table>
</div>
<p><span class="Bold">Acute Liver Injury:</span> In post-marketing
experience abnormal liver function tests have been reported, some
in the first few weeks of therapy with mexiletine hydrochloride.
Most of these have been observed in the setting of congestive heart
failure or ischemia and their relationship to mexiletine has not
been established.</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">PRECAUTIONS</a>
<div class="Section toggle-content closed" data-sectioncode=
"42232-9"><a name="A71E4743-7BA8-45F0-A618-7A56E7C993EC" id=
"A71E4743-7BA8-45F0-A618-7A56E7C993EC"></a> <a name="section-6" id=
"section-6"></a>
<div class="Section" data-sectioncode="34072-9"><a name=
"section-6.1" id="section-6.1"></a>
<h2>General</h2>
<p class="First">If a ventricular pacemaker is operative, patients
with second or third degree heart block may be treated with
mexiletine hydrochloride if continuously monitored. A limited
number of patients (45 of 475 in controlled clinical trials) with
pre-existing first degree AV block were treated with mexiletine;
none of these patients developed second or third degree AV block.
Caution should be exercised when it is used in such patients or in
patients with pre-existing sinus node dysfunction or
intraventricular conduction abnormalities.</p>
<p>Like other antiarrhythmics mexiletine hydrochloride can cause
worsening of arrhythmias. This has been uncommon in patients with
less serious arrhythmias (frequent premature beats or non-sustained
ventricular tachycardia (see<span class="Bold"><a href=
"#A2643155-97E9-4A8F-8206-FE5BC2AA2CA6">ADVERSE
REACTIONS</a></span>), but is of greater concern in patients with
life-threatening arrhythmias such as sustained ventricular
tachycardia. In patients with such arrhythmias subjected to
programmed electrical stimulation or to exercise provocation, 10 to
15% of patients had exacerbation of the arrhythmia, a rate not
greater than that of other agents.</p>
<p>Mexiletine should be used with caution in patients with
hypotension and severe congestive heart failure because of the
potential for aggravating these conditions.</p>
<p>Since mexiletine is metabolized in the liver, and hepatic
impairment has been reported to prolong the elimination half-life
of mexiletine, patients with liver disease should be followed
carefully while receiving mexiletine. The same caution should be
observed in patients with hepatic dysfunction secondary to
congestive heart failure.</p>
<p>Concurrent drug therapy or dietary regimens which may markedly
alter urinary pH should be avoided during mexiletine hydrochloride
therapy. The minor fluctuations in urinary pH associated with
normal diet do not affect the excretion of mexiletine.</p>
</div>
<div class="Section"><a name="section-6.2" id="section-6.2"></a>
<h2>SGOT Elevation and Liver Injury</h2>
<p class="First">In three-month controlled trials, elevations of
SGOT greater than three times the upper limit of normal occurred in
about 1% of both mexiletine-treated and control patients.
Approximately 2% of patients in the mexiletine compassionate use
program had elevations of SGOT greater than or equal to three times
the upper limit of normal. These elevations frequently occurred in
association with identifiable clinical events and therapeutic
measures such as congestive heart failure, acute myocardial
infarction, blood transfusions and other medications. These
elevations were often asymptomatic and transient, usually not
associated with elevated bilirubin levels and usually did not
require discontinuation of therapy. Marked elevations of SGOT
(&gt;1000 U/L) were seen before death in four patients with
end-stage cardiac disease (severe congestive heart failure,
cardiogenic shock).</p>
<p>Rare instances of severe liver injury, including hepatic
necrosis, have been reported in association with mexiletine
treatment. It is recommended that patients in whom an abnormal
liver test has occurred, or who have signs or symptoms suggesting
liver dysfunction, be carefully evaluated. If persistent or
worsening elevation of hepatic enzymes is detected, consideration
should be given to discontinuing therapy.</p>
</div>
<div class="Section"><a name="section-6.3" id="section-6.3"></a>
<h2>Blood Dyscrasias</h2>
<p class="First">Among 10,867 patients treated with mexiletine in
the compassionate use program, marked leukopenia (neutrophils less
than 1000/mm<span class="Sup">3</span>) or agranulocytosis were
seen in 0.06% and milder depressions of leukocytes were seen in
0.08%, and thrombocytopenia was observed in 0.16%. Many of these
patients were seriously ill and receiving concomitant medications
with known hematologic adverse effects. Rechallenge with mexiletine
in several cases was negative. Marked leukopenia or agranulocytosis
did not occur in any patient receiving mexiletine alone; five of
the six cases of agranulocytosis were associated with procainamide
(sustained release preparations in four) and one with vinblastine.
If significant hematologic changes are observed, the patient should
be carefully evaluated, and, if warranted, mexiletine should be
discontinued. Blood counts usually return to normal within one
month of discontinuation (see<span class="Bold"><a href=
"#A2643155-97E9-4A8F-8206-FE5BC2AA2CA6">ADVERSE
REACTIONS</a></span>).</p>
<p>Convulsions (seizures) did not occur in mexiletine controlled
clinical trials. In the compassionate use program, convulsions were
reported in about 2 of 1000 patients. Twenty-eight percent of these
patients discontinued therapy. Convulsions were reported in
patients with and without a prior history of seizures. Mexiletine
should be used with caution in patients with known seizure
disorder.</p>
</div>
<div class="Section" data-sectioncode="34073-7"><a name=
"A4E2E285-6BF7-4DF1-B3A7-4383231624A0" id=
"A4E2E285-6BF7-4DF1-B3A7-4383231624A0"></a> <a name="section-6.4"
id="section-6.4"></a>
<h2>Drug Interactions</h2>
<p class="First">Since mexiletine is a substrate for the metabolic
pathways involving CYP2D6 and CYP1A2 enzymes, inhibition or
induction of either of these enzymes would be expected to alter
mexiletine plasma concentrations. In a formal, single-dose
interaction study (n = 6 males) the clearance of mexiletine was
decreased by 38% following the coadministration of fluvoxamine, an
inhibitor of CYP1A2. In another formal study (n = 8 extensive and n
= 7 poor metabolizers of CYP2D6), coadministration of propafenone
did not alter the kinetics of mexiletine in the poor CYP2D6
metabolizer group. However, the metabolic clearance of mexiletine
in the extensive metabolizer phenotype decreased by about 70%
making the poor and extensive metabolizer groups indistinguishable.
In this crossover steady state study, the pharmacokinetics of
propafenone were unaffected in either phenotype by the
coadministration of mexiletine. Addition of mexiletine to
propafenone did not lead to further electrocardiographic parameters
changes of QRS, QTc, RR, and PR intervals than propafenone alone.
When concomitant administration of either of these two drugs with
mexiletine is initiated, the dose of mexiletine should be slowly
titrated to desired effect.</p>
<p>In a large compassionate use program mexiletine has been used
concurrently with commonly employed antianginal, antihypertensive,
and anticoagulant drugs without observed interactions. A variety of
antiarrhythmics such as quinidine or propranolol were also added,
sometimes with improved control of ventricular ectopy. When
phenytoin or other hepatic enzyme inducers such as rifampin and
phenobarbital have been taken concurrently with mexiletine
hydrochloride, lowered mexiletine plasma levels have been reported.
Monitoring of mexiletine plasma levels is recommended during such
concurrent use to avoid ineffective therapy.</p>
<p>In a formal study, benzodiazepines were shown not to affect
mexiletine plasma concentrations. ECG intervals (PR, QRS, and QT)
were not affected by concurrent mexiletine and digoxin, diuretics,
or propranolol.</p>
<p>Concurrent administration of cimetidine and mexiletine has been
reported to increase, decrease, or leave unchanged mexiletine
plasma levels; therefore patients should be followed carefully
during concurrent therapy.</p>
<p>Mexiletine does not alter serum digoxin levels but
magnesium-aluminum hydroxide, when used to treat gastrointestinal
symptoms due to mexiletine hydrochloride USP capsules, has been
reported to lower serum digoxin levels.</p>
<p>Concurrent use of mexiletine and theophylline may lead to
increased plasma theophylline levels. One controlled study in eight
normal subjects showed a 72% mean increase (range 35 to 136%) in
plasma theophylline levels. This increase was observed at the first
test point which was the second day after starting mexiletine.
Theophylline plasma levels returned to pre-mexiletine values within
48 hours after discontinuing mexiletine. If mexiletine and
theophylline are to be used concurrently, theophylline blood levels
should be monitored, particularly when the mexiletine dose is
changed. An appropriate adjustment in theophylline dose should be
considered.</p>
<p>Additionally, in one controlled study in five normal subjects
and seven patients, the clearance of caffeine was decreased 50%
following the administration of mexiletine.</p>
</div>
<div class="Section" data-sectioncode="34083-6"><a name=
"section-6.5" id="section-6.5"></a>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Studies of carcinogenesis in rats (24 months) and
mice, (18 months) did not demonstrate any tumorigenic potential.
Mexiletine was found to be non-mutagenic in the Ames test.
Mexiletine did not impair fertility in the rat.</p>
</div>
<div class="Section" data-sectioncode="42228-7"><a name=
"section-6.6" id="section-6.6"></a>
<h2>Pregnancy</h2>
<div class="Section" data-sectioncode="34077-8"><a name=
"section-6.6.1" id="section-6.6.1"></a>
<h3>Teratogenic Effects</h3>
<p class="First"><span class="Italics">PREGNANCY CATEGORY C:</span>
Reproduction studies performed with mexiletine hydrochloride in
rats, mice, and rabbits at doses up to four times the maximum human
oral dose (24 mg/Kg in a 50 Kg patient) revealed no evidence of
teratogenicity or impaired fertility but did show an increase in
fetal resorption. There are no adequate and well-controlled studies
in pregnant women; this drug should be used in pregnancy only if
the potential benefit justifies the potential risk to the
fetus.</p>
</div>
</div>
<div class="Section" data-sectioncode="34080-2"><a name=
"section-6.7" id="section-6.7"></a>
<h2>Nursing Mothers</h2>
<p class="First">Mexiletine appears in human milk in concentrations
similar to those observed in plasma. Therefore, if the use of
mexiletine is deemed essential, an alternative method of infant
feeding should be considered.</p>
</div>
<div class="Section" data-sectioncode="34081-0"><a name=
"section-6.8" id="section-6.8"></a>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients
have not been established.</p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">ADVERSE REACTIONS</a>
<div class="Section toggle-content closed" data-sectioncode=
"34084-4"><a name="A2643155-97E9-4A8F-8206-FE5BC2AA2CA6" id=
"A2643155-97E9-4A8F-8206-FE5BC2AA2CA6"></a> <a name="section-7" id=
"section-7"></a>
<p class="First">Mexiletine hydrochloride commonly produces
reversible gastrointestinal and nervous system adverse reactions
but is otherwise well tolerated. Mexiletine has been evaluated in
483 patients in one-month and three-month controlled studies and in
over 10,000 patients in a large compassionate use program. Dosages
in the controlled studies ranged from 600 to 1200 mg/day; some
patients (8%) in the compassionate use program were treated with
higher daily doses (1600 to 3200 mg/day). In the three-month
controlled trials comparing mexiletine to quinidine, procainamide
and disopyramide, the most frequent adverse reactions were upper
gastrointestinal distress (41%), lightheadedness (10.5%), tremor
(12.6%), and coordination difficulties (10.2%). Similar frequency
and incidence were observed in the one-month placebo-controlled
trial. Although these reactions were generally not serious, and
were dose-related and reversible with a reduction in dosage, by
taking the drug with food or antacid or by therapy discontinuation,
they led to therapy discontinuation in 40% of patients in the
controlled trials. Table 1 presents the adverse events reported in
the one-month placebo-controlled trial.</p>
<div class="scrollingtable">
<table frame="void">
<caption><span>Table 1: COMPARATIVE INCIDENCE (%) OF ADVERSE EVENTS
AMONG PATIENTS TREATED WITH MEXILETINE AND PLACEBO IN THE 4-WEEK,
DOUBLE-BLIND CROSSOVER TRIAL</span></caption>
<tbody class="Headless">
<tr class="First">
<td valign="top"></td>
<td align="center" valign="top">Mexiletine</td>
<td align="center" valign="top">Placebo</td>
</tr>
<tr>
<td valign="top"></td>
<td align="center" valign="top">N=53</td>
<td align="center" valign="top">N = 49</td>
</tr>
<tr>
<td valign="top"><span class="Bold">Cardiovascular</span></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td valign="top">Palpitations</td>
<td align="center" valign="top">7.5</td>
<td align="center" valign="top">10.2</td>
</tr>
<tr>
<td valign="top">Chest Pain</td>
<td align="center" valign="top">7 5</td>
<td align="center" valign="top">4.1</td>
</tr>
<tr>
<td valign="top">Increased Ventricular Arrhythmia/PVC’s</td>
<td align="center" valign="top">1.9</td>
<td align="center" valign="top">—</td>
</tr>
<tr>
<td valign="top"><span class="Bold">Digestive</span></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td valign="top">Nausea/Vomiting/Heartburn</td>
<td align="center" valign="top">39.6</td>
<td align="center" valign="top">6.1</td>
</tr>
<tr>
<td valign="top"><span class="Bold">Central Nervous
System</span></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td valign="top">Dizziness/Lightheadedness</td>
<td align="center" valign="top">26.4</td>
<td align="center" valign="top">14.3</td>
</tr>
<tr>
<td valign="top">Tremor</td>
<td align="center" valign="top">13.2</td>
<td align="center" valign="top">—</td>
</tr>
<tr>
<td valign="top">Nervousness</td>
<td align="center" valign="top">11.3</td>
<td align="center" valign="top">6.1</td>
</tr>
<tr>
<td valign="top">Coordination Difficulties</td>
<td align="center" valign="top">9.4</td>
<td align="center" valign="top">—</td>
</tr>
<tr>
<td valign="top">Changes in Sleep Habits</td>
<td align="center" valign="top">7.5</td>
<td align="center" valign="top">16.3</td>
</tr>
<tr>
<td valign="top">Paresthesias/Numbness</td>
<td align="center" valign="top">3.8</td>
<td align="center" valign="top">2.0</td>
</tr>
<tr>
<td valign="top">Weakness</td>
<td align="center" valign="top">1.9</td>
<td align="center" valign="top">4.1</td>
</tr>
<tr>
<td valign="top">Fatigue</td>
<td align="center" valign="top">1.9</td>
<td align="center" valign="top">2.0</td>
</tr>
<tr>
<td valign="top">Tinnitus</td>
<td align="center" valign="top">1.9</td>
<td align="center" valign="top">4.1</td>
</tr>
<tr>
<td valign="top">Confusion/Clouded Sensorium</td>
<td align="center" valign="top">1.9</td>
<td align="center" valign="top">2.0</td>
</tr>
<tr>
<td valign="top"><span class="Bold">Other</span></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td valign="top">Headache</td>
<td align="center" valign="top">7.5</td>
<td align="center" valign="top">6.1</td>
</tr>
<tr>
<td valign="top">Blurred Vision/Visual Disturbances</td>
<td align="center" valign="top">7.5</td>
<td align="center" valign="top">2.0</td>
</tr>
<tr>
<td valign="top">Dyspnea/Respiratory</td>
<td align="center" valign="top">5.7</td>
<td align="center" valign="top">10.2</td>
</tr>
<tr>
<td valign="top">Rash</td>
<td align="center" valign="top">3.8</td>
<td align="center" valign="top">2.0</td>
</tr>
<tr class="Last">
<td valign="top">Non-specific Edema</td>
<td align="center" valign="top">3.8</td>
<td align="center" valign="top">—</td>
</tr>
</tbody>
</table>
</div>
<p>Table 2 presents the adverse reactions occurring in one percent
or more of patients in the three-month controlled studies.</p>
<div class="scrollingtable">
<table frame="void">
<caption><span>Table 2: COMPARATIVE INCIDENCE (%) OF ADVERSE EVENTS
AMONG PATIENTS TREATED WITH MEXILETINE OR CONTROL DRUGS IN THE
12-WEEK DOUBLE-BLIND TRIALS</span></caption>
<tbody class="Headless">
<tr class="First">
<td valign="top"></td>
<td align="center" valign="top">Mexiletine</td>
<td align="center" valign="top">Quinidine</td>
<td align="center" valign="top">Procainamide</td>
<td align="center" valign="top">Disopyramide</td>
</tr>
<tr>
<td valign="top"></td>
<td align="center" valign="top">N = 430</td>
<td align="center" valign="top">N = 262</td>
<td align="center" valign="top">N = 78</td>
<td align="center" valign="top">N = 69</td>
</tr>
<tr>
<td valign="top"><span class="Bold">Cardiovascular</span></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td valign="top">Palpitations</td>
<td align="center" valign="top">4.3</td>
<td align="center" valign="top">4.6</td>
<td align="center" valign="top">1.3</td>
<td align="center" valign="top">5.8</td>
</tr>
<tr>
<td valign="top">Chest Pain</td>
<td align="center" valign="top">2.6</td>
<td align="center" valign="top">3.4</td>
<td align="center" valign="top">1.3</td>
<td align="center" valign="top">2.9</td>
</tr>
<tr>
<td valign="top">Angina/Angina-like Pain</td>
<td align="center" valign="top">1.7</td>
<td align="center" valign="top">1.9</td>
<td align="center" valign="top">2.6</td>
<td align="center" valign="top">2.9</td>
</tr>
<tr>
<td valign="top">Increased Ventricular</td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td valign="top">Arrhythmias/PVC’s</td>
<td align="center" valign="top">1.0</td>
<td align="center" valign="top">2.7</td>
<td align="center" valign="top">2.6</td>
<td align="center" valign="top">—</td>
</tr>
<tr>
<td valign="top"><span class="Bold">Digestive</span></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td valign="top">Nausea/Vomiting/Heartburn</td>
<td align="center" valign="top">39.3</td>
<td align="center" valign="top">21.4</td>
<td align="center" valign="top">33.3</td>
<td align="center" valign="top">14.5</td>
</tr>
<tr>
<td valign="top">Diarrhea</td>
<td align="center" valign="top">5.2</td>
<td align="center" valign="top">33.2</td>
<td align="center" valign="top">2.6</td>
<td align="center" valign="top">8.7</td>
</tr>
<tr>
<td valign="top">Constipation</td>
<td align="center" valign="top">4.0</td>
<td align="center" valign="top">—</td>
<td align="center" valign="top">6.4</td>
<td align="center" valign="top">11.6</td>
</tr>
<tr>
<td valign="top">Changes in Appetite</td>
<td align="center" valign="top">2.6</td>
<td align="center" valign="top">1.9</td>
<td align="center" valign="top">—</td>
<td align="center" valign="top">—</td>
</tr>
<tr>
<td valign="top">Abdominal Pain/</td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td valign="top">Cramps/Discomfort</td>
<td align="center" valign="top">1.2</td>
<td align="center" valign="top">1.5</td>
<td align="center" valign="top">—</td>
<td align="center" valign="top">1.4</td>
</tr>
<tr>
<td valign="top"><span class="Bold">Central Nervous
System</span></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td valign="top">Dizziness/Lightheadedness</td>
<td align="center" valign="top">18.9</td>
<td align="center" valign="top">14.1</td>
<td align="center" valign="top">14.1</td>
<td align="center" valign="top">2.9</td>
</tr>
<tr>
<td valign="top">Tremor</td>
<td align="center" valign="top">13.2</td>
<td align="center" valign="top">2.3</td>
<td align="center" valign="top">3.8</td>
<td align="center" valign="top">1.4</td>
</tr>
<tr>
<td valign="top">Coordination Difficulties</td>
<td align="center" valign="top">9.7</td>
<td align="center" valign="top">1.1</td>
<td align="center" valign="top">1.3</td>
<td align="center" valign="top">—</td>
</tr>
<tr>
<td valign="top">Changes in Sleep Habits</td>
<td align="center" valign="top">7.1</td>
<td align="center" valign="top">2.7</td>
<td align="center" valign="top">11.5</td>
<td align="center" valign="top">8.7</td>
</tr>
<tr>
<td valign="top">Weakness</td>
<td align="center" valign="top">5.0</td>
<td align="center" valign="top">5.3</td>
<td align="center" valign="top">7.7</td>
<td align="center" valign="top">2.9</td>
</tr>
<tr>
<td valign="top">Nervousness</td>
<td align="center" valign="top">5.0</td>
<td align="center" valign="top">1.9</td>
<td align="center" valign="top">6.4</td>
<td align="center" valign="top">5.8</td>
</tr>
<tr>
<td valign="top">Fatigue</td>
<td align="center" valign="top">3.8</td>
<td align="center" valign="top">5.7</td>
<td align="center" valign="top">5.1</td>
<td align="center" valign="top">1.4</td>
</tr>
<tr>
<td valign="top">Speech Difficulties</td>
<td align="center" valign="top">2.6</td>
<td align="center" valign="top">0.4</td>
<td align="center" valign="top">—</td>
<td align="center" valign="top">—</td>
</tr>
<tr>
<td valign="top">Confusion/Clouded</td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td valign="top">Sensorium</td>
<td align="center" valign="top">2.6</td>
<td align="center" valign="top">—</td>
<td align="center" valign="top">3.8</td>
<td align="center" valign="top">—</td>
</tr>
<tr>
<td valign="top">Paresthesias/</td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td valign="top">Numbness</td>
<td align="center" valign="top">2.4</td>
<td align="center" valign="top">2.3</td>
<td align="center" valign="top">2.6</td>
<td align="center" valign="top">—</td>
</tr>
<tr>
<td valign="top">Tinnitus</td>
<td align="center" valign="top">2.4</td>
<td align="center" valign="top">1.5</td>
<td align="center" valign="top">—</td>
<td align="center" valign="top">—</td>
</tr>
<tr>
<td valign="top">Depression</td>
<td align="center" valign="top">2.4</td>
<td align="center" valign="top">1.1</td>
<td align="center" valign="top">1.3</td>
<td align="center" valign="top">1.4</td>
</tr>
<tr>
<td valign="top"><span class="Bold">Other</span></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td valign="top">Blurred Vision/Visual</td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td valign="top">Disturbances</td>
<td align="center" valign="top">5.7</td>
<td align="center" valign="top">3.1</td>
<td align="center" valign="top">5.1</td>
<td align="center" valign="top">7.2</td>
</tr>
<tr>
<td valign="top">Headache</td>
<td align="center" valign="top">5.7</td>
<td align="center" valign="top">6.9</td>
<td align="center" valign="top">7.7</td>
<td align="center" valign="top">4.3</td>
</tr>
<tr>
<td valign="top">Rash</td>
<td align="center" valign="top">4.2</td>
<td align="center" valign="top">3.8</td>
<td align="center" valign="top">10.3</td>
<td align="center" valign="top">1.4</td>
</tr>
<tr>
<td valign="top">Dyspnea/Respiratory</td>
<td align="center" valign="top">3.3</td>
<td align="center" valign="top">3.1</td>
<td align="center" valign="top">5.1</td>
<td align="center" valign="top">2.9</td>
</tr>
<tr>
<td valign="top">Dry Mouth</td>
<td align="center" valign="top">2.8</td>
<td align="center" valign="top">1.9</td>
<td align="center" valign="top">5.1</td>
<td align="center" valign="top">14.5</td>
</tr>
<tr>
<td valign="top">Arthralgia</td>
<td align="center" valign="top">1.7</td>
<td align="center" valign="top">2.3</td>
<td align="center" valign="top">5.1</td>
<td align="center" valign="top">1.4</td>
</tr>
<tr class="Last">
<td valign="top">Fever</td>
<td align="center" valign="top">1.2</td>
<td align="center" valign="top">3.1</td>
<td align="center" valign="top">2.6</td>
<td align="center" valign="top">—</td>
</tr>
</tbody>
</table>
</div>
<p>Less than 1 %: Syncope, edema, hot flashes, hypertension,
short-term memory loss, loss of consciousness, other psychological
changes, diaphoresis, urinary hesitancy/retention, malaise,
impotence/decreased libido, pharyngitis, congestive heart
failure.</p>
<p>An additional group of over 10,000 patients has been treated in
a program allowing administration of mexiletine hydrochloride under
compassionate use circumstances. These patients were seriously ill
with the large majority on multiple drug therapy. Twenty-four
percent of the patients continued in the program for one year or
longer. Adverse reactions leading to therapy discontinuation
occurred in 15 percent of patients (usually upper gastrointestinal
system or nervous system effects). In general, the more common
adverse reactions were similar to those in the controlled trials.
Less common adverse events possibly related to mexiletine use
include:</p>
<p>Cardiovascular System: Syncope and hypotension, each about 6 in
1000; bradycardia, about 4 in 1000; angina/ angina-like pain, about
3 in 1000; edema, atrioventricular block/conduction disturbances
and hot flashes, each about 2 in 1000; atrial arrhythmias,
hypertension and cardiogenic shock, each about 1 in 1000.</p>
<p>Central Nervous System: Short-term memory loss, about 9 in 1000
patients; hallucinations and other psychological changes, each
about 3 in 1000; psychosis and convulsions/seizures, each about 2
in 1000; loss of consciousness, about 6 in 10,000.</p>
<p>Digestive: Dysphagia, about 2 in 1000; peptic ulcer, about 8 in
10,000; upper gastrointestinal bleeding, about 7 in 10,000;
esophageal ulceration, about 1 in 10,000. Rare cases of severe
hepatitis/acute hepatic necrosis.</p>
<p>Skin: Rare cases of exfoliative dermatitis and Stevens-Johnson
Syndrome with mexiletine hydrochloride treatment have been
reported.</p>
<p>Laboratory: Abnormal liver function tests, about 5 in 1000
patients; positive ANA and thrombocytopenia, each about 2 in 1000;
leukopenia (including neutropenia and agranulocytosis), about 1 in
1000; myelofibrosis, about 2 in 10,000 patients.</p>
<p>Other: Diaphoresis, about 6 in 1000; altered taste, about 5 in
1000; salivary changes, hair loss and impotence/decreased libido,
each about 4 in 1000; malaise, about 3 in 1000; urinary
hesitancy/retention, each about 2 in 1000; hiccups, dry skin,
laryngeal and pharyngeal changes and changes in oral mucous
membranes, each about 1 in 1000; SLE syndrome, about 4 in
10,000.</p>
<p><span class="Bold">Hematology:</span> Blood dyscrasias were not
seen in the controlled trials but did occur among 10,867 patients
treated with mexiletine in the compassionate use program
(see<span class="Bold"><a href=
"#A71E4743-7BA8-45F0-A618-7A56E7C993EC">PRECAUTIONS</a></span>).</p>
<p>Myelofibrosis was reported in two patients in the compassionate
use program: one was receiving long-term thiotepa therapy and the
other had pretreatment myeloid abnormalities.</p>
<p>In post-marketing experience, there have been isolated,
spontaneous reports of pulmonary changes including pulmonary
infiltration and pulmonary fibrosis during mexiletine therapy with
or without other drugs or diseases that are known to produce
pulmonary toxicity. A causal relationship to mexiletine therapy has
not been established. In addition, there have been isolated reports
of drowsiness, nystagmus, ataxia, dyspepsia, hypersensitivity
reaction, and exacerbation of congestive heart failure in patients
with pre-existing compromised ventricular function. There have been
rare reports of pancreatitis associated with mexiletine
treatment.</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">OVERDOSAGE</a>
<div class="Section toggle-content closed" data-sectioncode=
"34088-5"><a name="section-8" id="section-8"></a>
<p class="First">Clinical findings associated with mexiletine
hydrochloride overdosage have included drowsiness, confusion,
nausea, hypotension, sinus bradycardia, paresthesia, seizures,
bundle branch block, AV heart block, asystole, ventricular
tachyarrythmia, including ventricular fibrillation, cardiovascular
collapse, and coma. The lowest known dose in a fatality case was
4.4 g with postmortem serum mexiletine level of 34-37 mcg/mL
(Jequier P. et al. Lancet 1976: 1 (7956): 429). Patients have
recovered from ingestion of 4 g to 18 g of mexiletine (Frank S. E.
et al. Am J Emerg Med 1991: 9:43-48).</p>
<p>There is no specific antidote for mexiletine. Management of
mexiletine overdosage includes general supportive measures, close
observation and monitoring of vital signs. In addition, the use of
pharmacologic interventions (e.g., pressor agents, atropine or
anticonvulsants) or transvenous cardiac pacing is suggested,
depending on the patient’s clinical condition.</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">DOSAGE AND ADMINISTRATION</a>
<div class="Section toggle-content closed" data-sectioncode=
"34068-7"><a name="A039C1CD-DCE5-45D4-8911-C26E1400B353" id=
"A039C1CD-DCE5-45D4-8911-C26E1400B353"></a> <a name="section-9" id=
"section-9"></a>
<p class="First">The dosage of mexiletine hydrochloride must be
individualized on the basis of response and tolerance, both of
which are dose-related. Administration with food or antacid is
recommended. Initiate mexiletine therapy with 200 mg every eight
hours when rapid control of arrhythmia is not essential. A minimum
of two to three days between dose adjustments is recommended. Dose
may be adjusted in 50 or 100 mg increments up or down.</p>
<p>As with any antiarrhythmic drug, clinical and
electrocardiographic evaluation (including Holter monitoring if
necessary for evaluation) are needed to determine whether the
desired antiarrhythmic effect has been obtained and to guide
titration and dose adjustment.</p>
<p>Satisfactory control can be achieved in most patients by 200 to
300 mg given every eight hours with food or antacid. If
satisfactory response has not been achieved at 300 mg q8h, and the
patient tolerates mexiletine well, a dose of 400 mg q8h may be
tried. As the severity of CNS side effects increases with total
daily dose, the dose should not exceed 1200 mg/day.</p>
<p>In general, patients with renal failure will require the usual
doses of mexiletine hydrochloride. Patients with severe liver
disease, however, may require lower doses and must be monitored
closely. Similarly, marked right-sided congestive heart failure can
reduce hepatic metabolism and reduce the needed dose. Plasma level
may also be affected by certain concomitant drugs (see<span class=
"Bold"><a href="#A4E2E285-6BF7-4DF1-B3A7-4383231624A0">PRECAUTIONS:
Drug Interactions</a></span>).</p>
<p><span class="Bold">Loading Dose:</span> When rapid control of
ventricular arrhythmia is essential, an initial loading dose of 400
mg of mexiletine hydrochloride may be administered, followed by a
200 mg dose in eight hours. Onset of therapeutic effect is usually
observed within 30 minutes to two hours.</p>
<p><span class="Bold">Q12H Dosage Schedule:</span> Some patients
responding to mexiletine may be transferred to a 12 hour dosage
schedule to improve convenience and compliance. If adequate
suppression is achieved on a mexiletine hydrochloride dose of 300
mg or less every eight hours, the same total daily dose may be
given in divided doses every 12 hours while carefully monitoring
the degree of suppression of ventricular ectopy. This dose may be
adjusted up to a maximum of 450 mg every 12 hours to achieve the
desired response.</p>
<p><span class="Bold">Transferring to Mexiletine
hydrochloride:</span> The following dosage schedule, based on
theoretical considerations rather than experimental data, is
suggested for transferring patients from other Class 1 oral
antiarrhythmic agents to mexiletine: Mexiletine hydrochloride
treatment may be initiated with a 200 mg dose, and titrated to
response as described above, 6 to 12 hours after the last dose of
quinidine sulfate, 3 to 6 hours after the last dose of
procainamide, 6 to 12 hours after the last dose of disopyramide or
8 to 12 hours after the last dose of tocainide.</p>
<p>In patients in whom withdrawal of the previous antiarrhythmic
agent is likely to produce life-threatening arrhythmias,
hospitalization of the patient is recommended.</p>
<p>When transferring from lidocaine to mexiletine, the lidocaine
infusion should be stopped when the first oral dose of mexiletine
hydrochloride is administered. The infusion line should be left
open until suppression of the arrhythmia appears to be
satisfactorily maintained. Consideration should be given to the
similarity of the adverse effects of lidocaine and mexiletine and
the possibility that they may be additive.</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">HOW SUPPLIED</a>
<div class="Section toggle-content closed" data-sectioncode=
"34069-5"><a name="section-10" id="section-10"></a>
<p class="First">Mexiletine Hydrochloride Capsules USP are supplied
in hard gelatin capsules containing 150 mg, 200 mg or 250 mg of
mexiletine hydrochloride.</p>
<p>Mexiletine hydrochloride capsules USP, brown opaque cap and
light brown opaque body, imprinted with <span class="Bold">WATSON
491</span> and <span class="Bold">150 mg</span> are supplied in
bottles of 100.</p>
<p>Mexiletine hydrochloride capsules USP, brown opaque cap and
body, imprinted with <span class="Bold">WATSON 492</span> and
<span class="Bold">200 mg</span> are supplied in bottles of
100.</p>
<p>Mexiletine hydrochloride capsules USP, brown opaque cap and
light green opaque body, imprinted with <span class="Bold">WATSON
493</span> and <span class="Bold">250 mg</span> are supplied in
bottles of 100.</p>
<p><span class="Bold">Store at 25° C (77° F); excursions permitted
to 15-30° C (59-86°)</span> [see USP Controlled Room
Temperature].</p>
<p><span class="Bold">Watson Laboratories, Inc.</span><br>
Corona, CA 92880</p>
<p>Revised February 2006<br>
13073-4</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">INGREDIENTS AND APPEARANCE</a>
<div class="DataElementsTables toggle-content">
<div class="scrollingtable">
<table width="100%" cellpadding="3" cellspacing="0" class=
"contentTablePetite">
<tbody>
<tr>
<td class="contentTableTitle"><strong>MEXILETINE HCL</strong><br>
<span class="contentTableReg">mexiletine hydrochloride
capsule</span></td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="5"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product Information</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0591-0491</td>
</tr>
<tr class="formTableRow">
<td class="formLabel" width="30%">Route of Administration</td>
<td class="formItem">ORAL</td>
<td class="formLabel" width="30%">DEA Schedule</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="3">Active Ingredient/Active
Moiety</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Basis of Strength</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Mexiletine hydrochloride</strong>
(UNII: 606D60IS38) (Mexiletine - UNII:1U511HHV4Z)</td>
<td class="formItem"></td>
<td class="formItem">150 mg</td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>colloidal silicon dioxide</strong>
()</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>corn starch</strong> ()</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>D &amp; C Red No. 28</strong> ()</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D &amp; C Yellow No. 10</strong>
()</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD &amp; C Blue No. 1</strong> ()</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD &amp; C Red No. 40</strong> ()</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>gelatin</strong> (UNII:
2G86QN327L)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong> (UNII:
70097M6I30)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium lauryl sulfate</strong> (UNII:
368GB5141J)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>pregelatinized starch</strong> ()</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>titanium dioxide</strong> (UNII:
15FIX9V2JP)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>black iron oxide</strong> ()</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>red iron oxide</strong> ()</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>yellow iron oxide</strong> ()</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product
Characteristics</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">brown (brown/light brown)</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">18mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">WATSON;491</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Coating</td>
<td class="formItem">false</td>
<td class="formLabel">Symbol</td>
<td class="formItem">false</td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="5">Packaging</td>
</tr>
<tr>
<th class="formTitle" width="1" scope="col">#</th>
<th class="formTitle" scope="col">Item Code</th>
<th class="formTitle" scope="col">Package Description</th>
<th class="formTitle" scope="col">Marketing Start Date</th>
<th class="formTitle" scope="col">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th class="formItem" scope="row">1</th>
<td class="formItem">NDC:0591-0491-01</td>
<td class="formItem">100 in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th class="formItem" scope="row">2</th>
<td class="formItem">NDC:0591-0491-05</td>
<td class="formItem">500 in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td class="normalizer"></td>
</tr>
</tbody>
</table>
</div>
<div class="scrollingtable">
<table width="100%" cellpadding="3" cellspacing="0" class=
"contentTablePetite">
<tbody>
<tr>
<td class="contentTableTitle"><strong>MEXILETINE HCL</strong><br>
<span class="contentTableReg">mexiletine hydrochloride
capsule</span></td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="5"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product Information</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0591-0492</td>
</tr>
<tr class="formTableRow">
<td class="formLabel" width="30%">Route of Administration</td>
<td class="formItem">ORAL</td>
<td class="formLabel" width="30%">DEA Schedule</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="3">Active Ingredient/Active
Moiety</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Basis of Strength</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Mexiletine hydrochloride</strong>
(UNII: 606D60IS38) (Mexiletine - UNII:1U511HHV4Z)</td>
<td class="formItem"></td>
<td class="formItem">200 mg</td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>colloidal silicon dioxide</strong>
()</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>corn starch</strong> ()</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>D &amp; C Red No. 28</strong> ()</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D &amp; C Yellow No. 10</strong>
()</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD &amp; C Blue No. 1</strong> ()</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD &amp; C Red No. 40</strong> ()</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>gelatin</strong> (UNII:
2G86QN327L)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong> (UNII:
70097M6I30)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>pregelatinized starch</strong> ()</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium lauryl sulfate</strong> (UNII:
368GB5141J)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>titanium dioxide</strong> (UNII:
15FIX9V2JP)</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product
Characteristics</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">brown</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">19mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">WATSON;492</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Coating</td>
<td class="formItem">false</td>
<td class="formLabel">Symbol</td>
<td class="formItem">false</td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="5">Packaging</td>
</tr>
<tr>
<th class="formTitle" width="1" scope="col">#</th>
<th class="formTitle" scope="col">Item Code</th>
<th class="formTitle" scope="col">Package Description</th>
<th class="formTitle" scope="col">Marketing Start Date</th>
<th class="formTitle" scope="col">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th class="formItem" scope="row">1</th>
<td class="formItem">NDC:0591-0492-01</td>
<td class="formItem">100 in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th class="formItem" scope="row">2</th>
<td class="formItem">NDC:0591-0492-05</td>
<td class="formItem">500 in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td class="normalizer"></td>
</tr>
</tbody>
</table>
</div>
<div class="scrollingtable">
<table width="100%" cellpadding="3" cellspacing="0" class=
"contentTablePetite">
<tbody>
<tr>
<td class="contentTableTitle"><strong>MEXILETINE HCL</strong><br>
<span class="contentTableReg">mexiletine hydrochloride
capsule</span></td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="5"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product Information</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0591-0493</td>
</tr>
<tr class="formTableRow">
<td class="formLabel" width="30%">Route of Administration</td>
<td class="formItem">ORAL</td>
<td class="formLabel" width="30%">DEA Schedule</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="3">Active Ingredient/Active
Moiety</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Basis of Strength</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Mexiletine hydrochloride</strong>
(UNII: 606D60IS38) (Mexiletine - UNII:1U511HHV4Z)</td>
<td class="formItem"></td>
<td class="formItem">250 mg</td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>colloidal silicon dioxide</strong>
()</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>corn starch</strong> ()</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>D &amp; C Red No. 28</strong> ()</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D &amp; C Yellow No. 10</strong>
()</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD &amp; C Blue No. 1</strong> ()</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD &amp; C Red No. 40</strong> ()</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>gelatin</strong> (UNII:
2G86QN327L)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong> (UNII:
70097M6I30)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium lauryl sulfate</strong> (UNII:
368GB5141J)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>pregelatinized starch</strong> ()</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>titanium dioxide</strong> (UNII:
15FIX9V2JP)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD &amp; C Green No. 3</strong>
()</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product
Characteristics</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">brown (brown/light green)</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">22mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">WATSON;493</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Coating</td>
<td class="formItem">false</td>
<td class="formLabel">Symbol</td>
<td class="formItem">false</td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="5">Packaging</td>
</tr>
<tr>
<th class="formTitle" width="1" scope="col">#</th>
<th class="formTitle" scope="col">Item Code</th>
<th class="formTitle" scope="col">Package Description</th>
<th class="formTitle" scope="col">Marketing Start Date</th>
<th class="formTitle" scope="col">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th class="formItem" scope="row">1</th>
<td class="formItem">NDC:0591-0493-01</td>
<td class="formItem">100 in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th class="formItem" scope="row">2</th>
<td class="formItem">NDC:0591-0493-05</td>
<td class="formItem">500 in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td class="normalizer"></td>
</tr>
</tbody>
</table>
</div>
<div class="scrollingtable">
<table class="formTableMorePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingReg" colspan="4"><span class=
"formHeadingTitle">Labeler -</span> Watson Laboratories, Inc.</td>
</tr>
</tbody>
</table>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
</ul>
<div class="control-nav"><a class="open-all" href="#">View All
Sections</a><a class="close-all" href="#">Close All
Sections</a></div>
</div>
</div>
</article>
<div class="articlefooternav">
<h2>Find additional resources</h2>
<strong>(also available in the <a href="#leftmenu">left
menu</a>)</strong>
<h3>Safety</h3>
<p><a href="//www.accessdata.fda.gov/scripts/medwatch/" target=
"_blank">Report Adverse Events</a>, <a href=
"http://www.fda.gov/Safety/Recalls/" target="_blank">FDA Safety
Recalls</a>, <a href=
"http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+lactmed:@or+%28@na+%22Mexiletine%22+%29"
target="_blank">Presence in Breast Milk</a></p>
<h3>Related Resources</h3>
<p><a href=
"http://vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v:project=medlineplus&amp;query=Mexiletine"
target="_blank">Medline Plus</a>, <a href=
"//www.clinicaltrials.gov/ct/search?submit=Search&amp;term=Mexiletine"
target="_blank">Clinical Trials</a>, <a href="#pubmed-menu" id=
"pubmed-bottom">PubMed</a>, <a href=
"http://www.drugbank.ca/search?utf8=%E2%9C%93&amp;query=APRD00242&amp;search_type=drugs&amp;button="
target="_blank">Biochemical Data Summary</a></p>
<h3>More Info on this Drug</h3>
<p><a href="#modal-label-archives" class="modal-open">View Label
Archives</a>, <a href="#modal-rx-norm" class=
"modal-open">RxNorm</a>, <a href="#modal-label-rss" class=
"modal-open">Get Label RSS Feed</a></p>
</div>
</div>
<div class="divider"></div>
</div>
</div>
<!-- Label Archives Modal -->
<div class="mfp-hide modal" id="modal-label-archives">
<div class="modal-wrapper">
<header>
<h2>View Label Archives for this drug</h2>
</header>
<div class="top">
<h3 class="long-title">MEXILETINE HCL- mexiletine hydrochloride
capsule<br></h3>
<h4>Number of versions: 2</h4>
</div>
<div class="modal-content">
<table class="modal">
<tbody>
<tr>
<th>Published Date <a class="tip" rel="tooltip" href="#" title=
"&lt;b&gt;Published Date&lt;/b&gt; - The date that a drug label is published on DailyMed for public view. This is distinct from &lt;b&gt;Updated Date&lt;/b&gt;*. &lt;br&gt;&lt;br&gt; *&lt;b&gt;Updated Date&lt;/b&gt; (also known as &lt;b&gt;Effective Time&lt;/b&gt;) - The label revision date included in the SPL.">
(What is this?)</a></th>
<th>Version</th>
<th>Files</th>
</tr>
<tr>
<td>May 22, 2008</td>
<td>2 (current)</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=8156">download</a></td>
</tr>
<tr>
<td>May 17, 2007</td>
<td>1</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=4325">download</a></td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
<!-- RxNorm Modal -->
<div class="mfp-hide modal" id="modal-rx-norm">
<div class="modal-wrapper">
<header>
<h2>RxNorm</h2>
</header>
<div class="top">
<h3 class="long-title">MEXILETINE HCL- mexiletine hydrochloride
capsule<br></h3>
</div>
<div class="modal-content">
<table class="modal">
<tbody>
<tr>
<th></th>
<th>RxCUI</th>
<th>RxNorm NAME</th>
<th>RxTTY</th>
</tr>
<tr class="psn-rxtty">
<td>1</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=1362706">1362706</a></td>
<td>mexiletine HCl 150 MG Oral Capsule</td>
<td>PSN</td>
</tr>
<tr>
<td>2</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=1362706">1362706</a></td>
<td>Mexiletine Hydrochloride 150 MG Oral Capsule</td>
<td>SCD</td>
</tr>
<tr class="psn-rxtty">
<td>3</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=1362712">1362712</a></td>
<td>mexiletine HCl 200 MG Oral Capsule</td>
<td>PSN</td>
</tr>
<tr>
<td>4</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=1362712">1362712</a></td>
<td>Mexiletine Hydrochloride 200 MG Oral Capsule</td>
<td>SCD</td>
</tr>
<tr class="psn-rxtty">
<td>5</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=1362720">1362720</a></td>
<td>mexiletine HCl 250 MG Oral Capsule</td>
<td>PSN</td>
</tr>
<tr>
<td>6</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=1362720">1362720</a></td>
<td>Mexiletine Hydrochloride 250 MG Oral Capsule</td>
<td>SCD</td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
<!-- Label RSS Modal -->
<div class="mfp-hide modal" id="modal-label-rss">
<header>
<h2>Get Label RSS Feed for this Drug</h2>
</header>
<div class="top">
<h3 class="long-title">MEXILETINE HCL- mexiletine hydrochloride
capsule<br></h3>
</div>
<div class="modal-content">
<h4>To receive this label RSS feed</h4>
<p>Copy the URL below and paste it into your RSS Reader
application.</p>
<p><a href=
"https://dailymed.nlm.nih.gov/dailymed/labelrss.cfm?setid=AB73778B-6794-441C-B127-610A6D0733EA"
target=
"_blank">https://dailymed.nlm.nih.gov/dailymed/labelrss.cfm?setid=AB73778B-6794-441C-B127-610A6D0733EA</a></p>
<h4>To receive all DailyMed Updates for the last seven days</h4>
<p>Copy the URL below and paste it into your RSS Reader
application.</p>
<p><a href="https://dailymed.nlm.nih.gov/dailymed/rss.cfm" target=
"_blank">https://dailymed.nlm.nih.gov/dailymed/rss.cfm</a></p>
<h4>What will I get with the DailyMed RSS feed?</h4>
<p>DailyMed will deliver notification of updates and additions to
Drug Label information currently shown on this site through its RSS
feed.</p>
<p>DailyMed will deliver this notification to your desktop, Web
browser, or e-mail depending on the RSS Reader you select to use.
To view updated drug label links, paste the RSS feed address (URL)
shown below into a RSS reader, or use a browser which supports RSS
feeds, such as Safari for Mac OS X.</p>
<h4>How to discontinue the RSS feed</h4>
<p>If you no longer wish to have this DailyMed RSS service, simply
delete the copied URL from your RSS Reader.</p>
<a href="/dailymed/rss-updates.cfm" class="rss-icon"></a> <a href=
"/dailymed/rss-updates.cfm">More about getting RSS News &amp;
Updates from DailyMed</a></div>
</div>
<!-- RxImage no more notification modal -->
<div class="mfp-hide modal" id="no-pill-photo-warning-modal">
<div class="modal-content">
<h4>Why is DailyMed no longer displaying pill images on the Search
Results and Drug Info pages?</h4>
<br>
<p>Due to inconsistencies between the drug labels on DailyMed and
the pill images provided by <a href=
"https://rximage.nlm.nih.gov/docs/doku.php?id=rximageapi_support"
target="_blank">RxImage</a>, we no longer display the RxImage pill
images associated with drug labels.</p>
<p>We anticipate reposting the images once we are able identify and
filter out images that do not match the information provided in the
drug labels.</p>
</div>
</div>
<!-- this div is only for jQuery -->
<div class="search-results">
<div class="filter-drop"></div>
</div>
<div class="webview"></div>
<div class="hide-on-mobile"></div>
<div class="mobilenav no-js">
<ul>
<li><a href="/dailymed/index.cfm">Home</a></li>
<li>News
<ul>
<li><a href="/dailymed/dailymed-announcements.cfm">DailyMed
Announcements</a></li>
<li><a href="/dailymed/rss-updates.cfm">Get RSS News &amp;
Updates</a></li>
</ul>
</li>
<li>Search
<ul>
<li><a href="/dailymed/advanced-search.cfm">Advanced
Search</a></li>
<li><a href="/dailymed/browse-drug-classes.cfm">Browse Drug
Classes</a></li>
<li><a href="/dailymed/archives/index.cfm">Labels Archives</a></li>
<li><a href="http://pillbox.nlm.nih.gov">Tablet/Capsule ID
Tool</a></li>
</ul>
</li>
<li><a href="/dailymed/fda-drug-guidance.cfm">FDA Guidances &amp;
Information</a></li>
<li>NLM SPL Resources
<ul>
<li><a href="/dailymed/spl-resources.cfm">Download Data</a>
<ul>
<li><a href="/dailymed/spl-resources-all-drug-labels.cfm">All Drug
Labels</a></li>
<li><a href="/dailymed/spl-resources-all-indexing-files.cfm">All
Index Files</a></li>
<li><a href="/dailymed/spl-resources-all-mapping-files.cfm">All
Mapping Files</a></li>
</ul>
</li>
<li><a href="/dailymed/splimage-guidelines.cfm">SPL Image
Guidelines</a></li>
<li><a href=
"/dailymed/spl-resources-presentations-articles.cfm">Presentations
&amp; Articles</a></li>
</ul>
</li>
<li>Application Development Support
<ul>
<li><a href="/dailymed/app-support.cfm">Resources</a>
<ul>
<li><a href="/dailymed/app-support-web-services.cfm">Web
Services</a></li>
<li><a href="/dailymed/app-support-mapping-files.cfm">Mapping
Files</a></li>
</ul>
</li>
</ul>
</li>
<li><a href="/dailymed/help.cfm">Help</a></li>
</ul>
</div>
<footer class="mainFooter">
<div class="container">
<div class="three columns">
<div class="nihnlmlogoprint"><img src=
"/dailymed/images/nihnlmlogoprint.png" alt="NIH NLM Logo"></div>
<a href="//www.nlm.nih.gov/" class="logo" title=
"National Library of Medicine | National Institutes of Health"><img src="/dailymed/images/footer-logo.png"
width="109" height="37" alt=
"National Library of Medicine | National Institutes of Health"
title=
"National Library of Medicine | National Institutes of Health"></a></div>
<div id="share" class="thirteen columns">
<div class="footer-links">
<ul class="primary">
<li><a href="/dailymed/about-dailymed.cfm" title=
"About DailyMed">About DailyMed</a><span>|</span></li>
<li><a href="/dailymed/contact-us.cfm" title="Contact Us">Contact
Us</a><span>|</span></li>
<li><a href="//www.nlm.nih.gov/copyright.html" title="Copyright"
target="_blank" rel="bookmark">Copyright</a><span>|</span></li>
<li><a href="//www.nlm.nih.gov/privacy.html" title="Privacy"
target="_blank" rel="bookmark">Privacy</a><span>|</span></li>
<li><a href="//www.nlm.nih.gov/accessibility.html" title=
"Web Accessibility" target="_blank" rel="bookmark">Web
Accessibility</a></li>
</ul>
<ul class="secondary">
<li><a href="http://www.nih.gov/" title=
"National Institutes of Health" target="_blank" rel=
"bookmark">National Institutes of Health</a><span>|</span></li>
<li><a href="//www.nlm.nih.gov/" title=
"U.S. National Library of Medicine" target="_blank" rel=
"bookmark">U.S. National Library of Medicine</a><span>|</span></li>
<li><a href="http://www.hhs.gov/" title=
"Health &amp; Human Services" target="_blank" rel="bookmark">Health
&amp; Human Services</a></li>
</ul>
<ul class="secondary mobile">
<li><a href="http://www.nih.gov/" title=
"National Institutes of Health" target="_blank" rel=
"bookmark">NIH</a><span>|</span></li>
<li><a href="//www.nlm.nih.gov/" title=
"U.S. National Library of Medicine" target="_blank" rel=
"bookmark">NLM</a><span>|</span></li>
<li><a href="http://www.hhs.gov/" title=
"Health &amp; Human Services" target="_blank" rel="bookmark">Health
&amp; Human Services</a></li>
</ul>
<div class="social">Share <!-- AddThis Button BEGIN -->
 <noscript>: JavaScript needed for Sharing tools</noscript>
<div class=
"addthis_toolbox addthis_default_style addthis_16x16_style">
<a class="email-share" href=
"mailto:?subject=DailyMed%20Web%20site%20information&amp;Body=I%20would%20like%20to%20share%20this%20page%20from%20the%20DailyMed%20website%20with%20you%3A%0A%0AMEXILETINE%20HCL%2D%20Mexiletine%20Hydrochloride%20Capsule%0Ahttps%3A%2F%2Fdailymed%2Enlm%2Enih%2Egov%2Fdailymed%2FdrugInfo%2Ecfm%3Fsetid%3DAB73778B%2D6794%2D441C%2DB127%2D610A6D0733EA%0A%0ADailyMed%20is%20a%20site%20provided%20by%20The%20National%20Library%20of%20Medicine%20%28NLM%29%20and%20is%20the%20official%20provider%20of%20FDA%20drug%20label%20information%20%28package%20inserts%29%2E"
title="Share by Email"></a> <a class="addthis_button_facebook"></a>
<a class="addthis_button_twitter"></a> <a class=
"at300bs at15nc at15t_compact reveal" title="Bookmark &amp; Share"
href=
"//www.addthis.com/bookmark.php?pub=DailyMed&amp;title=DailyMed"
target="_blank" style="width: 16px; height: 16px"><span style=
"left: -9999px; position: absolute;">Bookmark &amp; Share</span>
<img style="width:17px; margin-top: -2px;" src=
"/dailymed/images/addthis-image.jpg" alt=
"Bookmark &amp; Share"></a></div>
<!-- AddThis Button END --></div>
</div>
</div>
</div>
<div class="divider"></div>
</footer>
<div class="divider"></div>
</div>
<div class="to-top"></div>
<!-- this div is only for jQuery -->
<div class="search-results">
<div class="filter-drop"></div>
</div>
<div class="webview"></div>
<div class="hide-on-mobile"></div>
<script type="text/javascript" src=
"//ajax.googleapis.com/ajax/libs/jquery/1.10.2/jquery.min.js">
</script> <script type="text/javascript">
        if (typeof jQuery == 'undefined')
        {  
            document.write('\x3Cscript type="text/javascript" src="/dailymed/scripts/jquery-1.10.2.min.js">\x3C/script>');
        }
</script> <script type="text/javascript">
        var basepath = "/dailymed";
;
        var availableClasses =  new Array();
;
        for(var i = 0; i < availableClasses.length; i++){
                availableClasses[i] = availableClasses[i].replace(/"/g, '').trim();
        }
        var labeltitle = "MEXILETINE HCL- mexiletine hydrochloride capsule <br>";
;
        var emailLink = "";
;
        var emailrequest = "0";
;
</script> <script src=
"/dailymed/scripts/javascript-html-attribute-encoding.min.js">
</script> <script src="/dailymed/scripts/spin.min.js">
</script> <script src="/dailymed/scripts/scripts.min.js?v=2">
</script> <script type='text/javascript' src=
"//ajax.googleapis.com/ajax/libs/jqueryui/1.11.0/jquery-ui.min.js">
</script> <script type="text/javascript">
        if (typeof jQuery.ui == 'undefined')
        {
            document.write('\x3Cscript type="text/javascript" src="/dailymed/scripts/jquery-ui-1.10.4.custom.min.js">\x3C/script>');
            document.write('\x3Clink rel="stylesheet" type="text/css" media="all" href="/dailymed/css/jquery-ui-1.10.4.custom.min.css">');
        }
        else{
            document.write('<link rel="stylesheet" href="//ajax.googleapis.com/ajax/libs/jqueryui/1.11.0/themes/smoothness/jquery-ui.min.css">');
        }
</script> <script type='text/javascript' src=
'/dailymed/scripts/jquery.elevateZoom-3.0.8.min.js'>
</script> <script type="text/javascript" src=
"/dailymed/scripts/jquery.placeholder.min.js">
</script> <script src=
"//www.accessdata.fda.gov/spl/stylesheet/spl.js" type=
"text/javascript" charset="utf-8">
/* */
</script> <!-- Magnific Popup core JS file -->
 <script src="/dailymed/scripts/jquery.magnific-popup.min.js">
</script> <script type="text/javascript">
var addthis_config = {"data_track_addressbar":false};
</script> <script type="text/javascript" src=
"//s7.addthis.com/js/300/addthis_widget.js#pubid=ra-542300cc2097c8b5">
</script> <script>
 var ignore_onbeforeunload = false;

 $("a").on('click',function(){
    if(ignore_onbeforeunload){
        ignore_onbeforeunload = false;
    }
})

$("a[href^='mailto'], a[href$='zip']").on('click',function(){
    ignore_onbeforeunload = true;
});


$(window).on('beforeunload', function(){
    if (!ignore_onbeforeunload){
        // Only run the loading icon if changing the page takes longer than 200ms
        setTimeout(function(){
            // Fade in the grey screen
            $('body').prepend($('<div class="loading-wrapper" style="width: 100%;height: 100%;background-color: rgba(0, 0, 0, 0.50);position: fixed;top:0;z-index: 100000;"><\/div>').fadeIn('fast'));
            var opts = {
                  lines: 12 // The number of lines to draw
                , length: 14 // The length of each line
                , width: 5 // The line thickness
                , radius: 14 // The radius of the inner circle
                , scale: 1 // Scales overall size of the spinner
                , corners: 1 // Corner roundness (0..1)
                , color: '#fff' 
                , opacity: 0.25 // Opacity of the lines
                , rotate: 0 // The rotation offset
                , direction: 1 // 1: clockwise, -1: counterclockwise
                , speed: 1 // Rounds per second
                , trail: 60 // Afterglow percentage
                , fps: 20 // Frames per second when using setTimeout() as a fallback for CSS
                , zIndex: 2e9 // The z-index (defaults to 2000000000)
                , className: 'spinner' // The CSS class to assign to the spinner
                , top: '50%' // Top position relative to parent
                , left: '50%' // Left position relative to parent
                , shadow: false // Whether to render a shadow
                , hwaccel: false // Whether to use hardware acceleration
                , position: 'absolute' // Element positioning
                }
            var spinner = new Spinner(opts).spin();
            $('.loading-wrapper').append(spinner.el);
        }, 200);
    }

    //ignore_onbeforeunload = false;
});
</script> <!-- START OF SmartSource Data Collector TAG -->
<!-- Copyright (c) 1996-2012 Webtrends Inc.  All rights reserved. -->
<!-- Version: 9.4.0 -->
<!-- Tag Builder Version: 3.3  -->
<!-- Created: 1/25/2012 11:57:33 PM -->
<script type="text/javascript" src=
"/dailymed/scripts/webtrends.min.js">
</script> 
<!-- =================================================================================== -->
<!-- Warning: The two script blocks below must remain inline. Moving them to an external -->
<!-- JavaScript include file can cause serious problems with cross-domain tracking.      -->
<!-- =================================================================================== -->
<script type="text/javascript">
//<![CDATA[
var _tag=new WebTrends();
_tag.dcsGetId();
//]]>
</script> <script type="text/javascript">
//<![CDATA[
_tag.dcsCustom=function(){
// Add custom parameters here.
//_tag.DCSext.param_name=param_value;
_tag.DCSext.dcsid=_tag.dcsid
}
_tag.trackAllEvents=true;
_tag.dcsCollect();
//]]>
</script> <noscript>
<div><img alt="DCSIMG" id="DCSIMG" width="1" height="1" src=
"//wtsdc.nlm.nih.gov/dcsm7fmt310000o265ioub7ib_2b7v/njs.gif?dcsuri=/nojavascript&amp;WT.js=No&amp;WT.tv=9.4.0&amp;dcssip=dailymed.nlm.nih.gov&amp;dcsid=dcsm7fmt310000o265ioub7ib_2b7v"></div>
</noscript> <!-- END OF SmartSource Data Collector TAG -->
 <script type="text/javascript">
    setTimeout(function(){var a=document.createElement("script");
    var b=document.getElementsByTagName("script")[0];
    a.src=document.location.protocol+"//dnn506yrbagrg.cloudfront.net/pages/scripts/0027/2050.js?"+Math.floor(new Date().getTime()/3600000);
    a.async=true;a.type="text/javascript";b.parentNode.insertBefore(a,b)}, 1);
</script> <script type="text/javascript">
    function getParameterByName(name) {
        name = name.replace(/[\[]/, "\\[").replace(/[\]]/, "\\]");
        var regex = new RegExp("[\\?&]" + name + "=([^&#]*)"),
            results = regex.exec(location.search);
        return results === null ? "" : decodeURIComponent(results[1].replace(/\+/g, " "));
    }
    /* Tracking label type on search pages */
    function CE_READY() {
        if(!getParameterByName('labeltype')){
           CE2.set(1, "No Label Type");
        }
        else{
            var labeltype = getParameterByName('labeltype');
            if(labeltype == 'all'){
                CE2.set(1, "All");
            }
            else if(labeltype == 'human'){
                CE2.set(1, "Human");
            }
            else if(labeltype == 'animal'){
                CE2.set(1, "Animal");
            }
            else{
                CE2.set(1, "Unknown");
            }
        }
    }
</script> <!-- DAP Universal Analytics -->
 <script language="javascript" id="_fed_an_ua_tag" src=
"/dailymed/scripts/Universal-Federated-Analytics-Min.2.01.js?agency=HHS&amp;subagency=NIH&amp;enhlink=true&amp;dclink=true">
</script> <script src="/dailymed/scripts/preview-text.min.js">
</script>
</body>
</html>
